Pancreatic Ductal Adenocarcinoma
📧 Sign up to get email alerts when something new happens for Pancreatic Ductal Adenocarcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors [Phase 1]
This ClinicalTrials.gov entry describes a Phase 1 study to determine a suitable dose of ASP5834 in adults with solid tumors, including non-s…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study [Phase 2]
A Phase 2 clinical trial update for the PIONEER-Panc study evaluating new and emerging therapies for pancreatic cancer at various stages (re…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors [Phase 1]
An ongoing Phase 1 trial is evaluating BL-M05D1 in patients with solid tumors, assessing safety, tolerability, pharmacokinetics, and prelimi…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors [Phase 1]
KO-2806 is being studied in Phase 1 trials as a monotherapy and in combination regimens for advanced solid tumors, including HRAS-altered ca…
-
CLINICAL_TRIALS research · 2026-04-14Clinical Trial Update: Resection/Synchronous Pulmonary or Hepatic Oligometastatic Pancreatic Ductal Adenocarcinoma [NA]
A recruiting clinical trial from The University of Texas Health Science Center at San Antonio is evaluating surgical resection for pancreati…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer [Phase 1]
A Phase 1 clinical trial is evaluating adding CA-4948 to standard chemotherapy for metastatic or unresectable pancreatic cancer and the stud…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
A clinical trial update describes a study evaluating microRNA as a diagnostic, prognostic, and treatment-response biomarker in pancreatic ca…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer [Phase 1]
Phase 1 clinical trial evaluating gemcitabine plus leflunomide for advanced unresectable pancreatic cancer is recruiting.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating BMS-986523 alone and in combination with anti-cancer agents in advanced solid malignancies, incl…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC [Phase 2]
Phase 2 trial evaluating autogene cevumeran plus atezolizumab with mFOLFIRINOX versus mFOLFIRINOX in patients with resected pancreatic ducta…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer [Phase 1, Phase 2]
A Phase 1/2 clinical trial assessing the safety and tolerability of JPI-547 in combination with Modified FOLFIRINOX or Gemcitabine-nab-pacli…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The KN510713 Study in Combination With mFOLFIRINOX [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating KN510713 in combination with mFOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocar…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]
A Phase 3 clinical trial evaluating chemotherapy with or without INCB161734 in untreated metastatic pancreatic ductal adenocarcinoma with KR…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating GDC-0449 (vismodegib) and erlotinib hydrochloride, with or without gemcitabine hydrochloride, in metastatic pancrea…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Cemiplimab Plus Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma [Phase 2]
A Phase 2 clinical trial evaluating cemiplimab plus gemcitabine for metastatic pancreatic ductal adenocarcinoma is currently recruiting.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer [Phase 3]
A Phase 3 trial is evaluating higher-dose radiation therapy for locally advanced unresectable pancreatic ductal adenocarcinoma, and recruitm…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue [Phase 2, Phase 3]
ClinicalTrials.gov update describes a Phase 2/Phase 3 study of Ponsegromab in adults with metastatic pancreatic ductal adenocarcinoma and ca…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Study of a Polygenic Risk Score to Predict the Risk of Pancreatic Ductal Adenocarcinoma [NA]
This clinical trial entry describes a study evaluating a polygenic risk score to predict the risk of pancreatic ductal adenocarcinoma, with …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors [Phase 1]
Phase 1 clinical trial update for PF-08046052/SGN-EGFRd2 in advanced solid tumors, including colorectal cancer, non-small cell lung cancer, …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer [Phase 1]
Phase 1 trial evaluating perioperative fostamatinib in combination with gemcitabine and nab-paclitaxel for resectable pancreatic ductal aden…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Early Detection of Pancreatic Adenocarcinoma (PDAC) Using a Panel of Biomarkers
This clinical trial update outlines an early detection study for pancreatic ductal adenocarcinoma using a biomarker panel, which is currentl…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: POP-UP: a Single-arm, Two-cohort Study: an 8-week Trimodal Pre-habilitation Program for Patients With Pancreatic Ductal Adenocarcinoma and Oesogastric [NA]
Update on the POP-UP trial, a single-arm, two-cohort study evaluating an 8-week trimodal prehabilitation program for patients with pancreati…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma [Phase 3]
A Phase 3 clinical trial evaluating Daraxonrasib alone and in combination with gemcitabine and nab-paclitaxel as first-line therapy for meta…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 3]
A Phase 3 clinical trial evaluating Daraxonrasib (RMC-6236) in patients with resected pancreatic ductal adenocarcinoma is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Advanced Therapies for Liver Metastases
Clinical trial update from IRCCS San Raffaele notes ongoing recruitment for advanced therapies targeting liver metastases, with indications …